STOCKHOLM, June 26, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) and CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) announced today the completion of the acquisition of CTI by Sobi through its indirect wholly owned subsidiary Cleopatra Acquisition Corp. (Cleopatra).
Swedish blood disorder specialist Sobi has enhanced its portfolio with a $1.7 billion acquisition of Seattle-based CTI BioPharma and its myelofibrosis treatment Vonjo, a potential blockbuster that was approved last year.
COPENHAGEN, May 10 (Reuters) - Drug maker Swedish Orphan Biovitrum (SOBIV.ST) (SOBI) said on Wednesday it had agreed to make a $1.7 billion cash offer to buy CTI BioPharma (CTIC.O), a U.S. biopharmaceutical company focused on blood related cancers and rare diseases.
SEATTLE, May 4, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on May 3, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).
SEATTLE, May 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on May 1, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).
SEATTLE, Wash., April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that the management team will participate in two upcoming investor conferences in April 2023.
SEATTLE, March 20, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to four new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on March 20, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).
CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)